Michael Barbella, Managing Editor03.26.21
A new assortment of physiological and emotional data is now accessible to clinical trial administrators thanks to Shimmer Research's extended Verisense platform. The company recently launched a new sensor, Verisense Plus+, which provides photoplethysmogram (PPG), galvanic skin response (GSR), and an inertial measurement unit (IMU).
The Verisense platform can now measure clinical trial participants’ heart rate, oxygen saturation and emotional responses in addition to their activity and sleep levels.
“We are excited to introduce Verisense Pulse+ to the clinical trial market and integrate these new senor capabilities into our platform,” said Geoffrey Gill, president of Shimmer Americas. “Worn on the wrist, Pulse+ has all the attributes that researchers look for in the Verisense platform. It is versatile and reliable (provides 24x7 continuous raw data) with water resistant, flexible styling. Verisense Pulse+ provides access to high quality raw data, while placing minimum burden on sponsors, clinical trial sites, and participants. It’s also easy to use because all the sensors are employed on the same architecture.”
The PPG sensor monitors heart rate by using light absorption to measure changes in participant capillary blood volume. Whereas the GSR sensor measures changes in sweat gland activity, which can be used to assess the participant’s level of psychological and emotional arousal, stress, and other emotional responses. GSR is used for psychology clinical research and biofeedback, and it is starting to be employed in more clinical applications, including epilepsy.
“After an extensive evaluation of all the on-market wearable sensor products, we determined that Verisense Pulse+ was the only one that could give us the raw data that we needed to study depression relapse thoroughly so we could create a tool to manage it effectively. We decided to become a Pulse+ beta tester and found the Shimmer team to be very collaborative and resourceful partners,” said Dr. Dilpreet Buxi, chief technology officer and co-founder of Philia Labs.
Verisense is a highly flexible, modular patent-pending platform designed from the ground up to meet the needs of clinical trials and remote patient research.
The Verisense platform can now measure clinical trial participants’ heart rate, oxygen saturation and emotional responses in addition to their activity and sleep levels.
“We are excited to introduce Verisense Pulse+ to the clinical trial market and integrate these new senor capabilities into our platform,” said Geoffrey Gill, president of Shimmer Americas. “Worn on the wrist, Pulse+ has all the attributes that researchers look for in the Verisense platform. It is versatile and reliable (provides 24x7 continuous raw data) with water resistant, flexible styling. Verisense Pulse+ provides access to high quality raw data, while placing minimum burden on sponsors, clinical trial sites, and participants. It’s also easy to use because all the sensors are employed on the same architecture.”
The PPG sensor monitors heart rate by using light absorption to measure changes in participant capillary blood volume. Whereas the GSR sensor measures changes in sweat gland activity, which can be used to assess the participant’s level of psychological and emotional arousal, stress, and other emotional responses. GSR is used for psychology clinical research and biofeedback, and it is starting to be employed in more clinical applications, including epilepsy.
“After an extensive evaluation of all the on-market wearable sensor products, we determined that Verisense Pulse+ was the only one that could give us the raw data that we needed to study depression relapse thoroughly so we could create a tool to manage it effectively. We decided to become a Pulse+ beta tester and found the Shimmer team to be very collaborative and resourceful partners,” said Dr. Dilpreet Buxi, chief technology officer and co-founder of Philia Labs.
Verisense is a highly flexible, modular patent-pending platform designed from the ground up to meet the needs of clinical trials and remote patient research.